1. |
Okano K, Maeba T, Ishimura K, et al.Hepatic resection for metastatic tumors from gastric cancer[J].AnnSurg, 2002, 235(1): 86-91.
|
2. |
Sakamoto Y, Sano T, Shimada K, et al.Favorable indications for hepatectomy in patients with liver metastasis from gastric cancer[J].J Surg Oncol, 2007, 95(7): 534-539.
|
3. |
周辉, 金哲俊, 翟博, 等.胃癌肝转移肝切除的预后分析[J].肝胆胰外科杂志, 2006, 18(3):147-149.
|
4. |
王洪义, 李明, 顾晋. 胃癌肝转移患者的手术治疗及预后分析[J].中华胃肠外科杂志, 2005, 8(1): 11-13.
|
5. |
Cheon SH, Rha SY, Jeung HC, et al.Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases[J].Ann Oncol, 2008, 19(6):1146-1153.
|
6. |
解世亮, 邵永孚, 冯强.胃癌肝转移的外科治疗[J].中华胃肠外科杂志, 2005, 8(1):14-16.
|
7. |
Chen L, Liu J.Value of palliative gastrectomy and transarterial chemoembolization for gastric cancer with synchronous liver metastases[C].9th International Gastric Cancer Congress, Korea.2011:123.
|
8. |
Kerkar SP, Kemp CD, Duffy A, et al.The GYMSSA trial:a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone[J].Trials, 2009, 23(10):121-129.
|
9. |
Mayo SC, Pawlik TM.Thermal ablative therapies for secondary hepatic malignancies[J].Cancer J, 2010, 16(2):111-117.
|
10. |
Kim HR, Ha Cheon S, Lee KH, et al.Efficacy and feasibility of radiofrequency ablation for liver metastases from gastric adenocarcinoma[J].Int J Hyperthermia, 2010, 26(4):305-315.
|
11. |
Boutros C, Somasundar P, Garrean S, et al.Microwave coagulation therapy for hepatic tumors: review of the literature and critical analysis[J].Surg Oncol, 2010, 19(1):e22-e32.
|
12. |
梁萍, 董宝玮, 于晓玲, 等.超声引导经皮微波消融治疗肝转移癌疗效评价[J].中华医学杂志, 2006, 86(12):806-810.
|
13. |
Ojima H, Ootake S, Yokobori T, et al.Treatment of multipleliver metastasis from gastric carcinoma[J].World J Surg Oncol, 2007, 5:70-73.
|
14. |
Yamakado K, Nakatsuka A, Takaki H, et al.Prospective study of arterial infusion chemotherapy followed by radiofrequency ablation for the treatment of liver metastasis of gastric cancer[J].J Vasc Interv Radiol, 2005, 16(12):1747-1751.
|
15. |
Hirasawa T, Asahara S, Fujisaki S, et al.Transcatheter arterial chemoembolization (TACE) using degradable starch microspheres (DSM) for metastatic liver tumors in patients with gastric cancer[J].Nippon Shokakibyo Gakkai Zasshi, 2008, 105(3):367-372.
|
16. |
Koizumi W, Narahara H, Hara T, et al.S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial):a phaseⅢ trial[J].Lancet Oncol, 2008, 9(3):215-221.
|
17. |
Ajani JA, Rodriguez W, Bodoky G, et al.Multicenter phase Ⅲ comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial[J].J Clin Oncol, 2010, 28(9):1547-1553.
|
18. |
Yoshida K, Ninomiya M, Takakura N, et al.Phase Ⅱ study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer[J].Clin Cancer Res, 2006, 12(11Pt1):3402-3407.
|
19. |
Fujii M.Chemotherapy for advanced gastric cancer: ongoing phaseⅢ study of S-1 alone versus S-1 and docetaxel combination (JACCRO GC03 study)[J].Int J Clin Oncol, 2008, 13(3):201-205.
|
20. |
LiZY, TangL, ZhangLH, et al.Weekly docetaxel and cisplatin plus fluorouracil as a preoperative treatment for gastric cancer patients with synchronous multiple hepatic metastases:a pilot study[J].Med Oncol, 2010, 27(4):1314-1318.
|
21. |
Sato Y, Takayama T, Sagawa T, et al.Phase Ⅱ study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer[J].Cancer Chemother Pharmacol, 2010, 66(4):721-728.
|
22. |
Pinto C, Di Fabio F, Siena S, et al.PhaseⅡ study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study)[J].Ann Oncol, 2007, 18(3):510-517.
|
23. |
Bang YJ, Van Cutsem E, Feyereislova A, et al.Trastuzumab incombination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro oesophageal junction cancer (ToGA):a phase 3, open-label, randomised controlled trial[J].Lancet, 2010, 376(9742):687-697.
|
24. |
Kang Y, Ohtsu A, Van Cutsem E, et al.AVAGAST:A randomized,double-blind,placebo-controlled,phaseⅢ study of first-line capecitabine and cisplatin plus bevacizumab or placebo in patients with advanced gastric cancer (AGC)[C].Proc ASCO,Annual Meeting 2010:LBA4007.
|
25. |
NCCN Practice Guidelines in Oncology (Gastric Cancer)-v. 2. 2010 www. nccn. org.
|
26. |
Glimelius B, Ekstrom K, Hoffman K, et al.Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer[J].Ann Oncol, 1997, 8(2):163-168.
|